Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

New neffy (epinephrine nasal spray) Data To Be Shared in 9 Presentations at 2025 AAAAI

By Patient Care Editorial Staff

February 26th 2025

Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.

Neffy Update: FDA to Review 1 mg Version in First Quarter 2025, for Young Children with Type 1 Allergic Reactions

By Patient Care Staff

January 14th 2025

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777